Longboard Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Casey Lynch, a director at Longboard Pharmaceuticals, disposed of multiple employee stock options as a result of the company's merger with a subsidiary of H. Lundbeck A/S.
A Longboard Pharmaceuticals director, Corinne Le Goff, disposed of multiple employee stock options as a result of the company's merger with a subsidiary of H. Lundbeck A/S.
Paul J. Sekhri, a director at Longboard Pharmaceuticals, cashed out his vested stock options for $60 per share following the company's merger with a subsidiary of H. Lundbeck A/S.
Phillip M. Schneider, a director at Longboard Pharmaceuticals, cashed out his vested stock options following the company's merger with a subsidiary of H. Lundbeck A/S.
A Form 4 filing reveals that a Longboard Pharmaceuticals director, Vincent Aurentz, had his unvested stock options accelerated and cashed out following the company's merger with a subsidiary of H. Lundbeck A/S.
An SEC Form 4 filing details the conversion of Longboard Pharmaceuticals executive Randall Kaye's stock options and restricted stock units into cash following the company's merger with a Lundbeck subsidiary.
Brandi Roberts, Executive VP and CFO of Longboard Pharmaceuticals, had her stock options and restricted stock units converted to cash as part of the company's merger with Lundbeck.
Longboard Pharmaceuticals CEO Kevin Lind's stock holdings and options were converted to cash following the company's merger with a subsidiary of H. Lundbeck A/S.
Longboard Pharmaceuticals' Chief Medical Officer, Randall Kaye, exercised stock options to acquire 30,554 shares of common stock.
Longboard Pharmaceuticals CEO, Kevin Robert Lind, exercised stock options and gifted shares to a donor-advised trust on November 13, 2024.